We are thrilled to announce that Moxie has successfully raised $10 million in our latest funding round, a testament to the growing demand for innovative solutions in the aesthetic industry. As a company dedicated to empowering nurses to become entrepreneurs in the booming medspa sector, we are committed to unlocking opportunities for those ready to take the leap into business ownership. This funding will significantly enhance our ability to support aesthetic entrepreneurs by expanding our platform and resources, ensuring they have the competitive edge needed to thrive in a challenging market filled with established chains. With a special focus on empowering female entrepreneurs—over 90% of those we support are women taking their first steps into business—Moxie has already helped more than 250 individuals successfully launch and grow their independent medspas. Our comprehensive approach, comprising strategic partnerships, a purpose-built platform, and unmatched pricing power, has positioned us as a leading resource for those with the tenacity and vision to succeed. As we continue to grow and evolve, this investment will enable us to enhance our offerings and expand our reach, driving economic growth for our entrepreneurs and their communities. Join us on this exciting journey as we redefine the landscape of aesthetic entrepreneurship. To learn more about our mission and how we can help you, visit www.joinmoxie.com.

Empowering Aesthetic Entrepreneurs: Moxie Secures $10M in Series B Funding Round
Get the full Moxie company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com
$150.0M Unknown
today

Lunar Outpost
Lunar Outpost is the industry leader in commercial space robotics, lunar surface mobility, and in-space infrastructure. We are on a mission to enable an extended human presence in space while utilizing the vast resources in space to drive positive impacts here on Earth. From our five rovers headed to the Moon to explore, prospect, and establish infrastructure, to the creation of oxygen on Mars, our impact spans the solar system. Lunar Outpost’s mobility and robotic systems, ranging from our exploration-class Mobile Autonomous Prospecting Platform (MAPP) rover to our truck-sized industrial Lunar Terrain Vehicle (LTV), will be the workforce for the New Space economy and enable Lunar Outpost to bring the infinite value of space to benefit humanity on Earth and beyond. Through notable commercialization and amazing partnerships, Lunar Outpost creates tremendous value in the New Space economy. Lunar Outpost leads the Lunar Dawn team, consisting of General Motors, Goodyear, and MDA Space – the leading consortium for LTV providing mobility for Artemis astronauts, a critical component of the broader Artemis campaign that will enable a sustainable presence on the Moon. Lunar Outpost’s five upcoming lunar surface missions will make history, with our first rover set to be the first commercial rover on the Moon and the first rover in history to explore the lunar South Pole, while enabling the first sale of space resources in human history alongside many other firsts. Each of our next four rover voyages build on our capabilities and technology, all leading towards mobility and robotic systems that can reliably operate in the most extreme environments our solar system has to offer.
$30.0M Series b
today

Darkhive
Darkhive develops US-produced open autonomous robotics systems for the defense and public safety communities.
$30.0M Series b
today

Founders First Capital Partners
National lender serving BIPOC, veteran, LGBTQ+, & women-owned businesses, as well as businesses in LMI zones & those committed to diverse hiring practices. Helping accelerate business growth through our Revenue-Based Funding products & Advisory Services. Together, we can create more jobs, increase your revenues and bottom line, and provide more growth capital to help your business. We’re backed by the nation’s top philanthropic organizations, so that we can fund you with the right capital.
$3.9M Unknown
today

Nelson
We help companies reduce their carbon footprints, control their mobility costs and use energy more efficiently. Our data-driven software enables companies to plan, deploy and operate a successful electrification strategy for their car fleet. Nelson combines companies' fleet data and the charging ecosystem data to provide personalized recommendations -in real time & automatically.
$3.5M Seed
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Lunar Outpost United States | Series b | $30.0M | today |
| 2 | ![]() Darkhive United States | Series b | $30.0M | today |
| 3 | ![]() GoKwik | Series b | $22.5M | today |
| 4 | ![]() EnviroSpark Energy Solutions United States | Series b | $3.0M | 1d ago |
| 5 | ![]() Moonshot AI United States | Series b | $2.0B | 1d ago |


